Papers: 31 Oct 2015 - 7 Nov 2015
Facial hypersensitivity and trigeminal pathology in mice with experimental autoimmune encephalomyelitis (EAE).
White matter integrity in polydrug users in relation to attachment and personality: a controlled diffusion tensor imaging study.
The natural dual cyclooxygenase and 5-lipoxygenase inhibitor flavocoxid is protective in EAE through effects on Th1/Th17 differentiation and macrophage/microglia activation.
[STUDY ON RELATIONSHIP BETWEEN DIFFUSION TENSOR IMAGING AND VISUAL EVOKED POTENTIAL IN VISUAL PATHWAY OF NEUROMYELITIS OPTICA].
ATP-Mediated Compositional Change in Peripheral Myelin Membranes: A Comparative Raman Spectroscopy and Time-Of-Flight Secondary Ion Mass Spectrometry Study.
Progesterone Enhanced Remyelination in the Mouse Corpus Callosum after Cuprizone Induced Demyelination.
Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol - studies in BV-2 microglia and encephalitogenic T cells.
Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.
The Association of Vitamin D Receptor Polymorphisms with Multiple Sclerosis in a Case-Control Study from Kuwait.
Effectiveness of muscle basal lamina carrying neural stem cells and olfactory ensheathing cells in spinal cord repair.
Monitoring oligoclonal immunoglobulins in cerebral spinal fluid using microLC-ESI-Q-TOF mass spectrometry.
Stress-induced anhedonia is associated with the activation of the inflammatory system in the rat brain: Restorative effect of pharmacological intervention.
Do coping styles mediate the relationship between disability status and psychosocial loss in people with relapsing remitting multiple sclerosis?
Effects of beta 2 adrenergic agonists on axonal injury and mitochondrial metabolism in experimental autoimmune encephalomyelitis rats.
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-Related Hospitalizations: Integrated Analysis of the Delayed-Release Dimethyl Fumarate Phase III Studies.
Optic neuritis as an initial manifestation of human herpesvirus 6 reactivation after unrelated bone marrow transplantation.
Diffusion kurtosis imaging probes cortical alterations and white matter pathology following cuprizone induced demyelination and spontaneous remyelination.
Correction: Increased Perfusion in Normal Appearing White Matter in High Inflammatory Multiple Sclerosis Patients.
Differential diagnosis and prognosis for longitudinally extensive myelitis in Buenos Aires, Argentina.
Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.
Cord blood mononuclear cells prevent neuronal apoptosis in response to perinatal asphyxia in the newborn lamb.
A Cross-Sectional Examination of the Associations Between Symptoms, Community Integration, and Mental Health in Multiple Sclerosis.
[Experience in the use of high-frequency selective percutaneous rhizotomy in trigeminal neuralgia associated with multiple sclerosis].
Sox13 functionally complements the related Sox5 and Sox6 as important developmental modulators in mouse spinal cord oligodendrocytes.
Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke.
Neuroprotection of Neuro2a cells and the cytokine suppressive and anti-inflammatory mode of action of resveratrol in activated RAW264.7 macrophages and C8-B4 microglia.
Signal transduction and epigenetic mechanisms in the control of microglia activation during neuroinflammation.
Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation.
The azetidine derivative, KHG26792 protects against ATP-induced activation of NFAT and MAPK pathways through P2X7 receptor in microglia.
The role of autologous haemopoietic stem cell transplantation in the treatment of autoimmune disorders.
Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells.
Immune Modulatory Mesenchymal Stem Cells Derived from Human Embryonic Stem Cells Through a Trophoblast-like Stage.
Quantification of diagnostic biomarkers to detect multiple sclerosis lesions employing (1)H-MRSI at 3T.
Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHA).
Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study.
MyelStones: the executive roles of myelin basic protein in myelin assembly and destabilization in multiple sclerosis.
Recurrent Guillain-Barré syndrome presenting stereotypic manifestations, positive antiganglioside antibodies, and rapid recovery.
Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis.
Tracking CNS and systemic sources of oxidative stress during the course of chronic neuroinflammation.
The nod-like receptor, Nlrp12, plays an anti-inflammatory role in experimental autoimmune encephalomyelitis.
p(70S6K1) in the TORC1 Pathway is Essential for the Differentiation of Th17 Cells, but Not Th1, Th2, or Treg Cells in Mice.
A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders.
Phosphodiesterase-5 inhibition promotes remyelination by MCP-1/CCR-2 and MMP-9 regulation in a cuprizone-induced demyelination model.
Cytosolic phospholipase A2 plays a crucial role in ROS/NO signaling during microglial activation through the lipoxygenase pathway.
Validation of a Dutch version of the Actionable 8-item screening questionnaire for neurogenic bladder overactivity in multiple sclerosis: an observational web-based study.
Scutellarin Alleviates Behavioral Deficits in a Mouse Model of Multiple Sclerosis, Possibly Through Protecting Neural Stem Cells.
Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.
Imaging of Proteins in Tissue Samples Using Nanospray Desorption Electrospray Ionization Mass Spectrometry.
Production, crystallization and neutron diffraction of fully deuterated human myelin peripheral membrane protein P2.
StatXFinder: a web-based self-directed tool that provides appropriate statistical test selection for biomedical researchers in their scientific studies.
Survey of Neurologist's Current Practices in Evaluation of Multiple Sclerosis to Identify Domains for a New Clinician-Reported Measure.
Costs Associated With Patients Diagnosed With Relapsing Remitting Multiple Sclerosis Taking Once Daily Fingolimod Capsules In The United States.
Cost-Effectiveness Analysis of Peginterferon Beta-1a In The Treatment of Relapsing-Remitting Multiple Sclerosis In Ireland.
Characteristics of Patients With Relapsing Remitting Multiple Sclerosis Taking Disease Modifying Agents.
Development of A Screening Tool to Support Identification of Patients With Secondary Progressive Multiple Sclerosis (Spms).
Differences In Multiple Sclerosis Relapse Rates Based On Patient Adherence, Average Daily Dose, And Persistence With Disease-Modifying Therapy: Observations Based on Real-World Data.
Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36.
Characteristics of Patients With Relapsing Remitting Multiple Sclerosis Taking Once Daily Fingolimod Capsules In The United States.
Characteristics of Geriatric Patients Diagnosed With Multiple Sclerosis Taking Disease Modifying Agents In The United States.
Association Between Self-Administered Expanded Disease Severity Scale (Edss) and Multiple Sclerosis Impact Scale (Msis-29): Results from The Burden of Illness In Patients With Multiple Sclerosis In Finland (Defense) Study.
Relapsing Remitting Multiple Sclerosis Patients Initiated on Oral Dmf Report A Better Quality of Life Compared to Patients on Platform Therapies As Measured By Eq-5d.
Natalizumab Use In Multiple Sclerosis: A Real World Evidence (Rwe) Analysis of Its Impact on Nhs Resources In England.
Challenges In Translating The Multiple Sclerosis International Quality of Life (Musiqol) Questionnaire In 57 Languages.
Budget Impact Analysis of Delayed-Release Dimethylfumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy.
A Cost-Effectiveness Analysis of Fingolimod Versus Dimethyl Fumarate As A Second-Line Disease Modifying Treatment In Patients With Highly Active Relapsing-Remitting Multiple Sclerosis.
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta.
Analysis of Expenditure In Multiple Sclerosis Disease Modifying Therapies Evolution Between 2004-2014 In Spain.
Inequalities In Access to Treatment for Multiple Sclerosis In England Continue Despite Service Improvement Initiatives And Policy Reforms.
Cost-Effectiveness of Dimethyl Fumarate Treatment for Relapsing-Remitting Multiple Sclerosis From A Danish Perspective.
Validation of Social Media Analysis for Outcomes Research: Identification of Drivers of Switches between oral and Injectable Therapies for Multiple Sclerosis.
Migration of the Fatigue Symptoms and Impacts Questionnaire-Relapsing Multiple Sclerosis (Fsiq-Rms(tm)) from Paper to an Electronic Diary Format.
Cost-Effectiveness Analysis of Peginterferon Beta-1a In The Treatment of Relapsing-Remitting Multiple Sclerosis In Scotland.
Real-World Assessment of Relapse, Medical Costs and Persistency of Multiple Sclerosis Patients Treated With Subcutaneous Interferon β-1a.
Cost-Effectiveness Analysis of Delayed-Release Dimethyl Fumarate for The Treatment of Relapsing Remitting Multiple Sclerosis In Spain.
Cost-Effectiveness Analysis of Delayed-Release Dimethyl-Fumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy.
Modeling The Natural History of Secondary-Progressive Multiple Sclerosis: A New Modeling Approach Using Discrete Event Simulation.
Cost-Utility Analysis of Delayed-Release Dimethyl Fumerate For The Treatment of Relapsing-Remitting Multiple Sclerosis In Portugal.
Comparison of Compliance And Discontinuation Rates Among Ms Patients Treated With Fingolimod and Other Disease-Modifying Therapies: A Canadian Retrospective Claims Analysis.
Treatment Satisfaction With Disease Modifying Therapies In Multiple Sclerosis: A Systematic Review of Studies Using The Treatment Satisfaction Questionnaire For Medication (Tsqm).
A Comparison of Stated Preferences for Injectable Disease-Modifying Treatments for Multiple Sclerosis: Compliant Vs. Non-Compliant Patients.
Health Care Resource Utilization Associated with Pediatric Patients Diagnosed with Relapsing Remitting Multiple Sclerosis.
Health Care Costs Associated With Geriatric Patients Diagnosed With Multiple Sclerosis Taking Disease Modifying Agents In The United States.
Comparison of Patients With Relapsing Remitting Multiple Sclerosis (Rrms) Treated With Disease Modifying Treatments (Dmt) In Europe (Eu) And The United States (Us).
Characteristics of Pediatric Patients With Relapsing Remitting Multiple Sclerosis Taking Disease Modifying Agents.
Development of Ms Budget Manager: A Practical Tool to Assist Alternative Stakeholders At Multiple Decision Levels In The Forecast And Financial Management For Multiple Sclerosis (Ms).
Adherence and Persistence among Patients Treated with First-Line Therapies for Relapsing-Remitting Multiple Sclerosis in Brazil.
Descriptive Evalaution of Characteristics of Patients Diagnosed with Relapsing Remitting Multiple Sclerosis and Taking Disease Modifying Agents.
Preferences of Patients With Multiple Sclerosis for Attributes of Disease Modifying Drugs In Decision-Making: A Nominal Group Technique And Best-Worst Scaling.
Cost Offset Analysis of Interferon Beta Disease Modifying Therapies In Relapsing-Remitting Multiple Sclerosis.
Cost of Drug-Related Monitoring Requirements for Glatiramer Acetate and Other Multiple Sclerosis Disease-Modifying Therapies (Dmts).
Glatiramer Acetate 40 Mg/Ml Three Times A Week for The Treatment of Relapsing Forms of Multiple Sclerosis: Potential Cost Benefits of A Regimen With Infrequent Injections Which May Minimise Switching to The Newly-Introduced First-Line and Second-Line Dise
Confirmed Disability Improvement In Patients With Active Multiple Sclerosis Treated With Fingolimod Versus Brace: A Matched Comparison of Treatments From The Pangaea And Pearl Registry Studies.
Comparative Effectiveness Using A Matching-Adjusted Indirect Comparison Between Delayed-Release Dimethyl Fumarate and Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis.
Cost-Effectiveness Analysis of Peginterferon Beta-1a In Italian Relapsing Remitting Multiple Sclerosis Management.
Rates of Adverse Events and Multiple Sclerosis Relapses Before and After Introduction of a Purported Generic Glatiramer Acetate in mexico: Results from a Large Patient Support Program in Mexico.
Cost-Utility of Fingolimod Compared With Dimethyl Fumarate (Dmf) In Highly Active Relapsing Remitting Multiple Sclerosis (Rrms) In England: Comparison of A Markov and Discrete Event Simulation Model.
Budget Impact Analysis for Peginterferon Beta-1a In Relapsing Remitting Multiple Sclerosis In Italy.
Treatment Costs and Patterns In Patients With Multiple Sclerosis Treated With Prolonged-Release Fampridine In Germany.
Adherence to Glatiramer Acetate 40 Mg Versus Oral Disease-Modifying Therapies for Multiple Sclerosis.
Impact of Ongoing National Health Technology Assessment Challenges on Patient Access to New Therapies for Multiple Sclerosis In Germany And The Uk.
Best Practices for Network Meta-Analysis Methodology: Comparative Effectiveness of Interferon-Beta Therapies In Relapsing-Remitting Multiple Sclerosis.
Effect Of Fingolimod On Disease Progressions, Relapse Rate And Brain Atrophy In Multiple Sclerosis Patients: Review Of Literature And Pharmacoeconomic Considerations.
Patterns Of Use Of Tests To Monitor Disease Activity Among Patients Currently Treated For Relapsing Remitting Multiple Sclerosis (Rrms) In Europe.
Characteristics of Patients With Relapsing Remitting Multiple Sclerosis (Rrms) Taking Injectable and Oral Disease Modifying Treatments (Dmt) In Europe (Eu).
Therapy Adherence In Patients With Multiple Sclerosis Using An Electronic Multidose Auto-Injection Device.
Pangaea 2.0: State Of The Art Multiple Sclerosis Patient Management In Daily Clinical Practice. A New 3-Year Observational Study Of Patients Receiving Fingolimod.
Characteristics of Patients with Relapsing Remitting Multiple Sclerosis Taking once Daily Teriflunomide Tablets in the United States.
A Long Term Analysis of The Clinical And Cost Effectiveness of Glatiramer Acetate From The Uk Multiple Sclerosis Risk Sharing Scheme.
Cost-Utility Analysis of Natalizumab as First-Line Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis in the Brazilian Public Healthcare System.
Heatlh Care Costs Associated with Patients Diagnosed with Relapsing Remitting Multiple Sclerosis Taking Once Daily Teriflunomide Tablets in the United States.
Comparison of Network Meta-Analysis and Traditional Meta-Analysis for Prevention of Relapses In Multiple Sclerosis.
Cost-Effectiveness of Escalating to Natalizumab or Switching Among Immunomodulators In Relapsing-Remitting Multiple Sclerosis In Italy.
The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management.
Neural progenitor cells isolated from the subventricular zone present hemichannel activity and form functional gap junctions with glial cells.
Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases.
A Disproportionate Burden of Care: Gender Differences in Mental Health, Health-Related Quality of Life, and Social Support in Mexican Multiple Sclerosis Caregivers.
Evaluation of the Degradation of the Selected Projectile, Commissural and Association White Matter Tracts Within Normal Appearing White Matter in Patients with Multiple Sclerosis Using Diffusion Tensor MR Imaging - a Preliminary Study.
Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta.
Association of interleukin-1 gene cluster polymorphisms and haplotypes with multiple sclerosis in an Iranian population.
Polymorphisms in CD28, CTLA-4, CD80 and CD86 genes may influence the risk of multiple sclerosis and its age of onset.
Daily fingolimod administration may cause lymphopenia but alternate-day administration may be too little to inhibit disease activity.
Long-distance effects of inflammation on differentiation of adult spinal cord neural stem/progenitor cells.